相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases
Amelie Menard et al.
AIDS (2009)
Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics
Marian Iwamoto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Effects of Omeprazole on Plasma Levels of Raltegravir
Marian Iwamoto et al.
CLINICAL INFECTIOUS DISEASES (2009)
Dose-Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral Exposure
A. A. Mathias et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Pharmacokinetics of Raltegravir in Individuals With UGT1A1 Polymorphisms
L. A. Wenning et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen
Marianne Harris et al.
AIDS (2008)
Emerging Pharmacology: Inhibitors of Human Immunodeficiency Virus Integration
Daria Hazuda et al.
Annual Review of Pharmacology and Toxicology (2008)
Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects
Matt S. Anderson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir
Marian Iwamoto et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro
Isabelle Malet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Lack of a significant drug interaction between raltegravir and tenofovir
Larissa A. Wenning et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Effect of ritonavir-boosted tipranavir or darunavir on the steady-state pharmacokinetics of elvitegravir
Anita A. Mathias et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2008)
Lack of a pharmacokinetic effect of raltegravir on midazolam: In vitro/in vivo correlation
Marian Iwamoto et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Discovery of Raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection
Vincenzo Summa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors
Olivia Goethals et al.
JOURNAL OF VIROLOGY (2008)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
David A. Cooper et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Raltegravir with optimized background therapy for resistant HIV-1 infection
Roy T. Steigbigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects
M. Iwamoto et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase
John M. Murray et al.
AIDS (2007)
Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir
Srinivasan Ramanathan et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Rapid and durable Antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection - Results of a 48-week controlled study
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2007)
Metabolism and disposition in humans of raltegravir (MK-0518), an Anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme
Kelem Kassahun et al.
DRUG METABOLISM AND DISPOSITION (2007)
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial
Beatriz Grinsztejn et al.
LANCET (2007)
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
Martin Markowitz et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients
Edwin DeJesus et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Mortality in the highly active antiretroviral therapy era - Changing causes of death and disease in the HIV outpatient study
Frank J. Palella et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2006)
Integrase inhibitors to treat HIV/AIDS
Y Pommier et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Structure and function of HIV-1 integrase
TK Chiu et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2004)
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals
M Louie et al.
AIDS (2003)
Repair of gaps in retroviral DNA integration intermediates
KE Yoder et al.
JOURNAL OF VIROLOGY (2000)
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells
DJ Hazuda et al.
SCIENCE (2000)
分享论文
